The article, published Monday, focused on the company Accelerated Evolution Biotechnologies Ltd. (AEBi)
"We believe we will offer a year's complete cure for cancer," said Dan Aridor, the company's chairman of the board,
treatment called "MuTaTo (multi-target toxin) is essentially on the scale of a cancer antibiotic – a breakup technology of the highest order."
Despite the report, doctors who spoke with ABC11 in North Carolina have expressed skepticism about claims
"Although it can always be something new, it's very unlikely that a company has developed something that is going to cure all cancers within a year.
Off-camera, a spokesperson for Duke Health, declined to comment on the report, citing a lack of scientific peer-review, calling it a " non-story. "
" I really think that it's really unfair and almost cruel to the bandy about these likely to be false hopes to cancer patients, "said Dr. Neel.
The Jerusalem Post article reports that the company has been tested on mice and is on the cusp of clinical trials
"As far as I know, this product has not been in patients. on the basis of test tube-based or animal studies that had absolutely no transferability to human disease, "Dr. Neil explained
In a statement to our sister station ABC1
"When they present it for peer review and it's published in a respectable journal and we can look at it, then that will be another story, "Neel said.
AEBi received a US patent on their platform last month
" Our cancer cure will be effective from day one, will last for a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market, "said Aridor.
Aridor is quoted in Jerusalem Post article as saying "Our solution will be both generic and personal,"
The National Cancer Institute estimated that more than 1.7 million people would be diagnosed with cancer in 2018, and more than 600,000 would die from the disease that year
Follow us on YouTube
Send a News Tip to Action News
Learn More About 6abc Apps